Injectable PrEP and other options are in the pipeline, and that makes clinical trials more complicated
Oct. 14, 2016
| By Mary Engel / Fred Hutch News Service
An injectable form of PrEP and other options are in the pipeline as the HIV field enters a new era of prevention. But such advances, as welcome as they are, come with a twist: They complicate the task of designing the clinical trials needed to test additional tools. Fred Hutch's Dr. Deborah Donnell explains.
SCHARP data shows longer nevirapine treatment reduces infection by half for babies with HIV-infected mothers, 75 percent for infants of untreated moms
March 14, 2011
Giving breastfeeding infants of HIV-infected mothers a daily dose of the antiretroviral drug nevirapine for six months halved the risk of HIV transmission to the infants at age 6 months compared with giving infants the drug daily for six weeks, according to preliminary clinical trial data presented March 2 at the Retroviruses and Opportunistic Infections conference in Boston.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.